Elixir Medical Corporation, a privately held medical company is scheduled to participate in the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, California.
Motasim Sirhan, President and Chief Executive Officer, will make a presentation about the company on Tuesday, January 13, 2015 at 8:30 a.m. PST (11:30 a.m. EST) in the Elizabethan C at the Westin St. Francis.
About Elixir Medical
Elixir Medical Corporation develops products that combine state-of-the-art medical devices with advanced pharmaceuticals to provide patients with innovative treatment solutions. The company was founded in 2005, and is based in Sunnyvale, California.
Elixir’s initial area of focus is coronary vascular intervention, with a broad portfolio of products leveraging Elixir’s unique pharmaceutical, drug release, stent platforms, and scaffold technologies:
- DESolve® 100: CE Mark-approved and the world’s first fully resorbable drug eluting scaffold system with a dramatically thinner strut profile of 100µm (one hundred microns)
- DESolve®: CE Mark-approved fully resorbable drug eluting scaffold system
- DESyne BD®: CE Mark-approved degradable coating drug eluting stent system
- DESyne®: CE Mark-approved durable polymer coating drug eluting stent system
Elixir is also developing resorbable scaffolds for peripheral vascular indications. The peripheral programs are currently in the preclinical phase.
For more information on the company and its products, please visit www.elixirmedical.com.
